3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
5
Multiple Myeloma
3
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Erdheim-Chester Disease
2
Xanthogranuloma, Juvenile
1
Thyroid Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Pancreatic Adenocarcinoma
1
Neoplasms, Unknown Primary
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoproliferative Disorders
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Laryngeal Neoplasms
1
Inflammatory Breast Neoplasms
1
Histiocytosis, Sinus
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Histiocytic Disorders, Malignant
1
Interventions
Temozolomide
43
Magnetic Resonance Spectroscopy
41
Radiotherapy
23
Specimen Handling
18
Biopsy
13
X-Rays
10
Radiation
10
trametinib
8
Bevacizumab
8
Nivolumab
7
Blood Specimen Collection
7
olaparib
6
fluorodopa F 18
6
dabrafenib
6
Radiotherapy, Intensity-Modulated
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Lomustine
6
pembrolizumab
5
abemaciclib
5
Standard of Care
5
vorasidenib
4
ulixertinib
4
larotrectinib
4
ivosidenib
4
erdafitinib
4
Surgical Procedures, Operative
4
Dianhydrogalactitol
4
Cyclophosphamide
4
Aminolevulinic Acid
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
cobimetinib
×
1 year
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled